United Immunity, Co., Ltd.
PrivateLast Round
VC Round
Sep 24, 2026
Total Funding Raised
$72.04M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
United Immunity, Co., Ltd. operates in Healthcare & Life Sciences and is based in Tokyo. Its latest recorded funding round was a VC Round in September 2026.
United Immunity, Co., Ltd. is a biotechnology company that develops nanotechnology-based immunotherapy for the treatment of cancer and infectious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
United Immunity, Co., Ltd. Comparables
Compare United Immunity, Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Resolute Science | 83% | |
| CREATE Medicines | 82% | |
| Macrophage Therapeutics, Inc. | 82% |
For institutional investors. Book with your work email.
United Immunity, Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Sep 24, 2026 | ||||
| Grant | Feb 27, 2026 | ||||
| Debt | Mar 15, 2024 | ||||
| VC Round | Sep 11, 2023 | ||||
| Series B | Sep 7, 2021 | ||||
Series A Extension | Mar 31, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
United Immunity, Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Japan Agency for Medical Research and Development | Grant |
| Saisei Ventures | VC Round |
| Kobe University Capital | VC Round |
| Mizuho Capital | VC Round |
| UTEC (The University of Tokyo Edge Capital Partners) | VC Round |
| Joyo Bank, Ltd. | VC Round |
| 日本ベンチャーキャピタル株式会社 | VC Round |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 24, 2026
$14M round led by Itochu Corporation.
- Jul 25, 2026
Monthly visitors grew 71% MoM, reaching 2.8K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 10, 2026
United Immunity Co. is developing its P-LNP platform to enable the in vivo generation of CAR-macrophages for applications in cancer, fibrosis and autoimmune diseases.
- receives_financingSep 24, 2026
On Sep 24th '26 in Japan, United Immunity Co. receives $13.4M in financing from ITOCHU through a private placement to accelerate global clinical development and the practical application of new therapies.
- is_developingSep 24, 2026
As of Sep 24th '26, United Immunity Co. is developing the in vivo CAR-macrophage therapy using its Myeloid Targeting Platform(TM) to transform immune cells in the body into cells that attack cancer cells.
- invests_into_assetsAug 25, 2026
United Immunity Co. acquires macrophage assets from Carisma Therapeutics for the treatment of cancer and liver fibrosis in Japan on Aug 25th '26.
- is_developingAug 25, 2026
On Aug 25th '26 in Japan, United Immunity Co. secures an exclusive global license from Columbia University to develop and commercialize genetically engineered in vivo TIM4 macrophages to prevent and treat MASH by restoring TIM4 expression in liver macrophages.
For institutional investors. Book with your work email.
United Immunity, Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about United Immunity, Co., Ltd.'s valuation, stock price, and market status.
Is United Immunity, Co., Ltd. a public or private company?
United Immunity, Co., Ltd. is a private company.
What is the current stock price of United Immunity, Co., Ltd.?
United Immunity, Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks United Immunity, Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is United Immunity, Co., Ltd. worth (valuation)?
Valuation information for United Immunity, Co., Ltd. is not publicly available.
Can I buy United Immunity, Co., Ltd. stock?
United Immunity, Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was United Immunity, Co., Ltd.'s last funding round?
United Immunity, Co., Ltd.'s most recent funding round was VC Round on September 24, 2026.
Who are the main investors in United Immunity, Co., Ltd.?
Key investors in United Immunity, Co., Ltd. include Japan Agency for Medical Research and Development, Saisei Ventures, Kobe University Capital, Mizuho Capital, UTEC (The University of Tokyo Edge Capital Partners).
Will United Immunity, Co., Ltd. IPO soon?
No public IPO plans have been announced for United Immunity, Co., Ltd..
How can I track United Immunity, Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in United Immunity, Co., Ltd.'s shares on secondary markets.